Susan Searles Nielsen1, Anat Gross1, Alejandra Camacho-Soto1, Allison W Willis2,3, Brad A Racette1,4. 1. Department of Neurology, Washington University School of Medicine, St Louis, MO. 2. Departments of Neurology and of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA. 3. Center for Pharmacoepidemiology Research and Training, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA. 4. School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Parktown, South Africa.
Abstract
OBJECTIVE: A recent study observed a 2-fold greater risk of Parkinson disease (PD) in relation to the β2-adrenoreceptor antagonist propranolol and a markedly lower risk of PD for the β2-adrenoreceptor agonist salbutamol. We examined whether confounding by clinical indication for these medications, that is, tremor and smoking-related pulmonary conditions, explained these associations. METHODS: In a large, population-based case-control study of United States Medicare beneficiaries in 2009 with diagnosis codes, procedure codes, and prescription data (48,295 incident PD cases, 52,324 controls), we examined the risk of PD in relation to use of selected β antagonists (propranolol, carvedilol, metoprolol), the β2 agonist salbutamol, and other medications used for the same clinical indications (primidone, inhaled corticosteroids). We adjusted for demographics, smoking, and overall use of medical care. We then examined the effect of also adjusting for clinical indication and applying medication exposure lagging. RESULTS: Propranolol appeared to increase PD risk (odds ratio [OR] = 3.62, 95% confidence interval [CI] = 3.31-3.96). When we adjusted for tremor or abnormal involuntary movement prior to the PD diagnosis/reference date and lagged propranolol exposure, the association was 0.97 (95% CI = 0.80-1.18). Primidone, also used for tremor, was similarly sensitive to this adjustment and lagging. β Antagonists not indicated for tremor appeared to reduce PD risk (carvedilol: OR = 0.77, 95% CI = 0.73-0.81; metoprolol: OR = 0.94, 95% CI = 0.91-0.97) and were insensitive to adjustment for indications and lagging. Neither salbutamol nor inhaled corticosteroids were consistently associated with PD risk. INTERPRETATION: β2-adrenoreceptor agonists and antagonists do not appear to alter PD risk. Ann Neurol 2018;84:691-701.
OBJECTIVE: A recent study observed a 2-fold greater risk of Parkinson disease (PD) in relation to the β2-adrenoreceptor antagonist propranolol and a markedly lower risk of PD for the β2-adrenoreceptor agonist salbutamol. We examined whether confounding by clinical indication for these medications, that is, tremor and smoking-related pulmonary conditions, explained these associations. METHODS: In a large, population-based case-control study of United States Medicare beneficiaries in 2009 with diagnosis codes, procedure codes, and prescription data (48,295 incident PD cases, 52,324 controls), we examined the risk of PD in relation to use of selected β antagonists (propranolol, carvedilol, metoprolol), the β2 agonist salbutamol, and other medications used for the same clinical indications (primidone, inhaled corticosteroids). We adjusted for demographics, smoking, and overall use of medical care. We then examined the effect of also adjusting for clinical indication and applying medication exposure lagging. RESULTS:Propranolol appeared to increase PD risk (odds ratio [OR] = 3.62, 95% confidence interval [CI] = 3.31-3.96). When we adjusted for tremor or abnormal involuntary movement prior to the PD diagnosis/reference date and lagged propranolol exposure, the association was 0.97 (95% CI = 0.80-1.18). Primidone, also used for tremor, was similarly sensitive to this adjustment and lagging. β Antagonists not indicated for tremor appeared to reduce PD risk (carvedilol: OR = 0.77, 95% CI = 0.73-0.81; metoprolol: OR = 0.94, 95% CI = 0.91-0.97) and were insensitive to adjustment for indications and lagging. Neither salbutamol nor inhaled corticosteroids were consistently associated with PD risk. INTERPRETATION: β2-adrenoreceptor agonists and antagonists do not appear to alter PD risk. Ann Neurol 2018;84:691-701.
Authors: T A Zesiewicz; R J Elble; E D Louis; G S Gronseth; W G Ondo; R B Dewey; M S Okun; K L Sullivan; W J Weiner Journal: Neurology Date: 2011-10-19 Impact factor: 9.910
Authors: Shuchi Mittal; Kjetil Bjørnevik; Doo Soon Im; Adrian Flierl; Xianjun Dong; Joseph J Locascio; Kristine M Abo; Elizabeth Long; Ming Jin; Bing Xu; Yang K Xiang; Jean-Christophe Rochet; Anders Engeland; Patrizia Rizzu; Peter Heutink; Tim Bartels; Dennis J Selkoe; Barbara J Caldarone; Marcie A Glicksman; Vikram Khurana; Birgitt Schüle; David S Park; Trond Riise; Clemens R Scherzer Journal: Science Date: 2017-09-01 Impact factor: 47.728
Authors: Beate Ritz; Alberto Ascherio; Harvey Checkoway; Karen S Marder; Lorene M Nelson; Walter A Rocca; G Webster Ross; Daniel Strickland; Stephen K Van Den Eeden; Jay Gorell Journal: Arch Neurol Date: 2007-07
Authors: Alejandra Camacho-Soto; Mark N Warden; Susan Searles Nielsen; Amber Salter; David L Brody; Heidi Prather; Brad A Racette Journal: Ann Neurol Date: 2017-10-31 Impact factor: 10.422
Authors: Francesco Giorgianni; Pierre Ernst; Sophie Dell'Aniello; Samy Suissa; Christel Renoux Journal: Am J Epidemiol Date: 2020-08-01 Impact factor: 4.897
Authors: Clive Ballard; Dag Aarsland; Jeffrey Cummings; John O'Brien; Roger Mills; Jose Luis Molinuevo; Tormod Fladby; Gareth Williams; Pat Doherty; Anne Corbett; Janet Sultana Journal: Nat Rev Neurol Date: 2020-09-16 Impact factor: 42.937